Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody

Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to reduce the burden placed on health systems, the situation remains critical. Effective diagnosis, treatment, and prophylactic measures are urgently required to meet global demand: recombinant antibodies fulfill...

Descripción completa

Detalles Bibliográficos
Autores principales: Valenzuela Nieto, Guillermo, Jara, Ronald, Watterson, Daniel, Modhiran, Naphak, Amarilla, Alberto A., Himelreichs, Johanna, Khromykh, Alexander A., Salinas-Rebolledo, Constanza, Pinto, Teresa, Cheuquemilla, Yorka, Margolles, Yago, López González del Rey, Natalia, Miranda-Chacon, Zaray, Cuevas, Alexei, Berking, Anne, Deride, Camila, González-Moraga, Sebastián, Mancilla, Héctor, Maturana, Daniel, Langer, Andreas, Toledo, Juan Pablo, Müller, Ananda, Uberti, Benjamín, Krall, Paola, Ehrenfeld, Pamela, Blesa, Javier, Chana-Cuevas, Pedro, Rehren, German, Schwefel, David, Fernandez, Luis Ángel, Rojas-Fernandez, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870875/
https://www.ncbi.nlm.nih.gov/pubmed/33558635
http://dx.doi.org/10.1038/s41598-021-82833-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870875/
https://www.ncbi.nlm.nih.gov/pubmed/33558635
http://dx.doi.org/10.1038/s41598-021-82833-w

Ejemplares similares